Company Encyclopedia
View More
name
Lishengpharma
002393.SZ
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers its products in various forms comprising tablets, capsules, granules, and injections for use in various therapeutic fields, such as nervous system, musculoskeletal, genitourinary system, antineoplastic and immune system, sensory system, systemic anti-infection, respiratory system, endocrine system, digestive system, and cardiovascular system, as well as drugs for invigorating qi and blood. It also provides antibiotics and Chinese patent medicines; injections for cerebrovascular, hormone, biochemistry, animal organ and plant extraction, and other fields; and raw materials and anesthetic drugs.
3.157 T
002393.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking140/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.77%B
    • Profit Margin29.25%A
    • Gross Margin61.19%A
  • Growth ScoreC
    • Revenue YoY4.30%C
    • Net Profit YoY104.88%A
    • Total Assets YoY-1.59%D
    • Net Assets YoY0.01%C
  • Cash ScoreC
    • Cash Flow Margin341.87%C
    • OCF YoY4.30%C
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio15.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lishengpharma: Company executives plan to reduce their holdings by no more than 11,200 shares of the company

    36Kr learned that Lishengpharma announced that the company's senior management personnel, Guo Xiaoyan, plans to reduce holdings of the company's shares by no more than 11,200 shares through centralized bidding, with the intended reduction not exceeding 0.0044% of the total share capital after excluding the shares in the repurchase special account

    36Kr·
    SZ
    002393
    +0.49%
    36Kr·
    SZ
    002393
    +0.49%

    Lishengpharma released its performance for the first three quarters, with a net profit attributable to the parent company of 371 million yuan, a year-on-year increase of 119.05%

    According to the Zhitong Finance APP, Lishengpharma disclosed its third-quarter report for 2025. The company achieved a revenue of 1.007 billion yuan in the first three quarters, a year-on-year decrease of 1.61%; the net profit attributable to shareholders of the listed company was 371 million yuan, a year-on-year increase of 119.05%; the net profit excluding non-recurring gains and losses was 127 million yuan, a year-on-year increase of 19.21%; the basic earnings per share were 1.44 yuan

    Zhitong·
    SZ
    002393
    +0.49%
    Zhitong·
    SZ
    002393
    +0.49%

    Tianjin Development's subsidiary Lishengpharma plans to invest 174 million yuan to participate in the establishment of a fund

    Tianjin Development's subsidiary Lishengpharma plans to invest CNY 174 million to participate in the establishment of a fund with a total subscribed capital of CNY 500 million. The fund will primarily invest in equity of unlisted companies and non-publicly issued stocks of listed companies in the fields of health and biotechnology in China. Lishengpharma's investment risk will be limited to its subscribed capital, and investments must be approved by the investment decision committee. Teda Private Equity, as the manager, has a good track record of investment returns

    Zhitong·
    SZ
    002393
    +0.49%
    Zhitong·
    SZ
    002393
    +0.49%

    Lishengpharma: Potassium Chloride Sustained-Release Tablets have passed the market approval application

    Lishengpharma announced that the company has obtained the drug registration certificates for potassium chloride sustained-release tablets in specifications of 0.5g and 0.6g issued by the National Medical Products Administration, marking the approval of the drug for market licensing application. This drug is suitable for the treatment and prevention of hypokalemia, especially in cases where dietary management or reduced diuretic treatment is ineffective

    Zhitong·
    SZ
    002393
    +0.49%
    Zhitong·
    SZ
    002393
    +0.49%

    Tianjin Development: Lishengpharma's mid-term net profit attributable to the parent company is 343 million yuan, an increase of 235.04% year-on-year

    According to the Zhitong Finance APP, Tianjin Development announced the performance of its indirectly non-wholly-owned subsidiary Tianjin Lishengpharma Co., Ltd. (Lishengpharma) for the six months ending June 30, 2025, with total operating revenue of RMB 732 million, a year-on-year decrease of 1.76%; net profit attributable to the owners of the parent company of RMB 343 million, a year-on-year increase of 235.04%; and basic earnings per share of RMB 1.33

    Zhitong·
    SZ
    002393
    +0.49%
    Zhitong·
    SZ
    002393
    +0.49%
    © 2025 Longbridge｜Disclaimer